---
pmid: '33186521'
title: An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation.
authors:
- Bonfiglio JJ
- Leidecker O
- Dauben H
- Longarini EJ
- Colby T
- San Segundo-Acosta P
- Perez KA
- Matic I
journal: Cell
year: '2020'
full_text_available: false
doi: 10.1016/j.cell.2020.09.055
---

# An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation.
**Authors:** Bonfiglio JJ, Leidecker O, Dauben H, Longarini EJ, Colby T, San Segundo-Acosta P, Perez KA, Matic I
**Journal:** Cell (2020)
**DOI:** [10.1016/j.cell.2020.09.055](https://doi.org/10.1016/j.cell.2020.09.055)

## Abstract

1. Cell. 2020 Nov 12;183(4):1086-1102.e23. doi: 10.1016/j.cell.2020.09.055.

An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation.

Bonfiglio JJ(1), Leidecker O(1), Dauben H(1), Longarini EJ(1), Colby T(1), San 
Segundo-Acosta P(1), Perez KA(2), Matic I(3).

Author information:
(1)Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck 
Institute for Biology of Ageing, 50931 Cologne, Germany.
(2)Protein Expression and Purification Core Facility, EMBL Heidelberg, 69126 
Heidelberg, Germany.
(3)Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck 
Institute for Biology of Ageing, 50931 Cologne, Germany; Cologne Excellence 
Cluster for Stress Responses in Ageing-Associated Diseases (CECAD), University 
of Cologne, 50931 Cologne, Germany. Electronic address: imatic@age.mpg.de.

Strategies for installing authentic ADP-ribosylation (ADPr) at desired positions 
are fundamental for creating the tools needed to explore this elusive 
post-translational modification (PTM) in essential cellular processes. Here, we 
describe a phospho-guided chemoenzymatic approach based on the Ser-ADPr writer 
complex for rapid, scalable preparation of a panel of pure, precisely modified 
peptides. Integrating this methodology with phage display technology, we have 
developed site-specific as well as broad-specificity antibodies to mono-ADPr. 
These recombinant antibodies have been selected and characterized using multiple 
ADP-ribosylated peptides and tested by immunoblotting and immunofluorescence for 
their ability to detect physiological ADPr events. Mono-ADPr proteomics and 
poly-to-mono comparisons at the modification site level have revealed the 
prevalence of mono-ADPr upon DNA damage and illustrated its dependence on PARG 
and ARH3. These and future tools created on our versatile chemical 
biology-recombinant antibody platform have broad potential to elucidate ADPr 
signaling pathways in health and disease.

Copyright Â© 2020 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.cell.2020.09.055
PMID: 33186521 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of Interests I.M., J.J.B., and T.C. 
are inventors on EU patent applications PCT/EP2018/078592 and PCT/EP2019/074885 
filled by the Max Planck Society and related to the technology for site-specific 
generation of Ser-ADP-ribosylated peptides.
